Science & Technology
Targeting eNAMPT-TLR4 signaling with the novel ALT-100 mAb to slow IPF progression
Department of Health and Human Services — National Institutes of Health
Opportunity #: 1R41HL180035-01
Award Ceiling
$285K
Award Floor
$285K
Close Date
Sep 19, 2026
188 days leftTotal Funding
$285K
Expected Awards
1
Posted Date
Sep 20, 2025
Cost Sharing Required
No
Grants.gov ID
sbir-1R41HL180035-01
Description
STTR Phase Phase I award: "Targeting eNAMPT-TLR4 signaling with the novel ALT-100 mAb to slow IPF progression" awarded to AQUALUNG THERAPEUTICS, CORP in JUNO BEACH, Florida. Funded by Department of Health and Human Services (National Institutes of Health). Award amount: $284,699. The SBIR/STTR programs fund innovative research and development by small businesses, with Phase I for feasibility studies and Phase II for full R&D.
Eligible Applicants
Small businesses
Apply on Grants.gov
Always verify details and apply through the official Grants.gov portal. Information here may not reflect the latest changes.
View on Grants.govDisclaimer: This information is sourced from Grants.gov and may not reflect the most current details. Always verify eligibility requirements, deadlines, and application procedures on the official program website before applying.